http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 28 May 2026 12:45:04 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Tevogen+pursues+acquisitions+targeting+%24100+million+annual+revenue/26564510.html <p>Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced it is evaluating strategic acquisitions that could generate approximately $100 million in combined annual revenue if completed. The Warren, N.J.-based company said the initiatives include a previously announced evaluation of a contract research organization and additional acquisition opportunities.</p><p>The potential acquisitions are part of Tevogen's strategy to create a financially self-sufficient healthcare enterprise comprising its biotechnology arm Tevogen Bio, technology arm Tevogen.AI, and a proposed healthcare services division that may include management services and contract research operations.</p><p>"Capital discipline and preserving the integrity of our capital structure are core priorities for us," said Ryan Saadi, http://www.streetinsider.com/Corporate+News/Tevogen+pursues+acquisitions+targeting+%24100+million+annual+revenue/26564510.html Thu, 28 May 2026 12:45:04 -0400 TVGN TVGNW http://www.streetinsider.com/Corporate+News/Tevogen+pursues+acquisitions+targeting+%24100+million+annual+revenue/26564510.html <p>Tevogen Bio Holdings Inc. (NASDAQ: TVGN) announced it is evaluating strategic acquisitions that could generate approximately $100 million in combined annual revenue if completed. The Warren, N.J.-based company said the initiatives include a previously announced evaluation of a contract research organization and additional acquisition opportunities.</p><p>The potential acquisitions are part of Tevogen's strategy to create a financially self-sufficient healthcare enterprise comprising its biotechnology arm Tevogen Bio, technology arm Tevogen.AI, and a proposed healthcare services division that may include management services and contract research operations.</p><p>"Capital discipline and preserving the integrity of our capital structure are core priorities for us," said Ryan Saadi, http://www.streetinsider.com/Corporate+News/Tevogen+pursues+acquisitions+targeting+%24100+million+annual+revenue/26564510.html Thu, 28 May 2026 12:45:04 -0400 TVGN TVGNW http://www.streetinsider.com/Press+Releases/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html <p>WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=EUcdivTuGvletcA08jAdFYmbip2qCrwA5b-gIoecUvUCkaSPXT7zk6IPCHYsP84OVLNTRsUiXTm4_1zlY9Rzzw==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4dIpR_vpvIwuP9gBnkY-EepARo1hOOySfkS2LU7XslZoS2NyrmvJLe9pEWs5pX7X09YJsEASBJghEUn6HC6i087BSZzSN7zDFOiV2p7rCPQoHIU8lpmwU3I4uLAoASpg" rel="nofollow" target="_blank">TVGN</a>) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue. These initiatives include the Company’s previously announced evaluation of a contract research organization (“CRO”), along with additional strategic acquisition opportunities aligned with Tevogen’s broader healthcare platform.</p> <p>Tevogen believes these and other strategic acquisition initiatives could support the Company’s evolution into http://www.streetinsider.com/Press+Releases/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html Thu, 28 May 2026 12:30:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Press+Releases/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html <p>WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=EUcdivTuGvletcA08jAdFYmbip2qCrwA5b-gIoecUvUCkaSPXT7zk6IPCHYsP84OVLNTRsUiXTm4_1zlY9Rzzw==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4dIpR_vpvIwuP9gBnkY-EepARo1hOOySfkS2LU7XslZoS2NyrmvJLe9pEWs5pX7X09YJsEASBJghEUn6HC6i087BSZzSN7zDFOiV2p7rCPQoHIU8lpmwU3I4uLAoASpg" rel="nofollow" target="_blank">TVGN</a>) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue. These initiatives include the Company’s previously announced evaluation of a contract research organization (“CRO”), along with additional strategic acquisition opportunities aligned with Tevogen’s broader healthcare platform.</p> <p>Tevogen believes these and other strategic acquisition initiatives could support the Company’s evolution into http://www.streetinsider.com/Press+Releases/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html Thu, 28 May 2026 12:30:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Press+Releases/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html <p>WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=EUcdivTuGvletcA08jAdFYmbip2qCrwA5b-gIoecUvUCkaSPXT7zk6IPCHYsP84OVLNTRsUiXTm4_1zlY9Rzzw==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4dIpR_vpvIwuP9gBnkY-EepARo1hOOySfkS2LU7XslZoS2NyrmvJLe9pEWs5pX7X09YJsEASBJghEUn6HC6i087BSZzSN7zDFOiV2p7rCPQoHIU8lpmwU3I4uLAoASpg" rel="nofollow" target="_blank">TVGN</a>) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue. These initiatives include the Company’s previously announced evaluation of a contract research organization (“CRO”), along with additional strategic acquisition opportunities aligned with Tevogen’s broader healthcare platform.</p> <p>Tevogen believes these and other strategic acquisition initiatives could support the Company’s evolution into http://www.streetinsider.com/Press+Releases/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html Thu, 28 May 2026 12:30:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Press+Releases/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html <p>WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=EUcdivTuGvletcA08jAdFYmbip2qCrwA5b-gIoecUvUCkaSPXT7zk6IPCHYsP84OVLNTRsUiXTm4_1zlY9Rzzw==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4dIpR_vpvIwuP9gBnkY-EepARo1hOOySfkS2LU7XslZoS2NyrmvJLe9pEWs5pX7X09YJsEASBJghEUn6HC6i087BSZzSN7zDFOiV2p7rCPQoHIU8lpmwU3I4uLAoASpg" rel="nofollow" target="_blank">TVGN</a>) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue. These initiatives include the Company’s previously announced evaluation of a contract research organization (“CRO”), along with additional strategic acquisition opportunities aligned with Tevogen’s broader healthcare platform.</p> <p>Tevogen believes these and other strategic acquisition initiatives could support the Company’s evolution into http://www.streetinsider.com/Press+Releases/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html Thu, 28 May 2026 12:30:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Press+Releases/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html <p>WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=EUcdivTuGvletcA08jAdFYmbip2qCrwA5b-gIoecUvUCkaSPXT7zk6IPCHYsP84OVLNTRsUiXTm4_1zlY9Rzzw==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4dIpR_vpvIwuP9gBnkY-EepARo1hOOySfkS2LU7XslZoS2NyrmvJLe9pEWs5pX7X09YJsEASBJghEUn6HC6i087BSZzSN7zDFOiV2p7rCPQoHIU8lpmwU3I4uLAoASpg" rel="nofollow" target="_blank">TVGN</a>) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue. These initiatives include the Company’s previously announced evaluation of a contract research organization (“CRO”), along with additional strategic acquisition opportunities aligned with Tevogen’s broader healthcare platform.</p> <p>Tevogen believes these and other strategic acquisition initiatives could support the Company’s evolution into http://www.streetinsider.com/Press+Releases/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html Thu, 28 May 2026 12:30:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Globe+Newswire/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html <p>WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=EUcdivTuGvletcA08jAdFYmbip2qCrwA5b-gIoecUvUCkaSPXT7zk6IPCHYsP84OVLNTRsUiXTm4_1zlY9Rzzw==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4dIpR_vpvIwuP9gBnkY-EepARo1hOOySfkS2LU7XslZoS2NyrmvJLe9pEWs5pX7X09YJsEASBJghEUn6HC6i087BSZzSN7zDFOiV2p7rCPQoHIU8lpmwU3I4uLAoASpg" rel="nofollow" target="_blank">TVGN</a>) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue. These initiatives include the Company’s previously announced evaluation of a contract research organization (“CRO”), along with additional strategic acquisition opportunities aligned with Tevogen’s broader healthcare platform.</p> <p>Tevogen believes these and other strategic acquisition initiatives could support the Company’s evolution into http://www.streetinsider.com/Globe+Newswire/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html Thu, 28 May 2026 12:30:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Globe+Newswire/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html <p>WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=EUcdivTuGvletcA08jAdFYmbip2qCrwA5b-gIoecUvUCkaSPXT7zk6IPCHYsP84OVLNTRsUiXTm4_1zlY9Rzzw==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4dIpR_vpvIwuP9gBnkY-EepARo1hOOySfkS2LU7XslZoS2NyrmvJLe9pEWs5pX7X09YJsEASBJghEUn6HC6i087BSZzSN7zDFOiV2p7rCPQoHIU8lpmwU3I4uLAoASpg" rel="nofollow" target="_blank">TVGN</a>) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue. These initiatives include the Company’s previously announced evaluation of a contract research organization (“CRO”), along with additional strategic acquisition opportunities aligned with Tevogen’s broader healthcare platform.</p> <p>Tevogen believes these and other strategic acquisition initiatives could support the Company’s evolution into http://www.streetinsider.com/Globe+Newswire/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html Thu, 28 May 2026 12:30:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Globe+Newswire/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html <p>WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=EUcdivTuGvletcA08jAdFYmbip2qCrwA5b-gIoecUvUCkaSPXT7zk6IPCHYsP84OVLNTRsUiXTm4_1zlY9Rzzw==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4dIpR_vpvIwuP9gBnkY-EepARo1hOOySfkS2LU7XslZoS2NyrmvJLe9pEWs5pX7X09YJsEASBJghEUn6HC6i087BSZzSN7zDFOiV2p7rCPQoHIU8lpmwU3I4uLAoASpg" rel="nofollow" target="_blank">TVGN</a>) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue. These initiatives include the Company’s previously announced evaluation of a contract research organization (“CRO”), along with additional strategic acquisition opportunities aligned with Tevogen’s broader healthcare platform.</p> <p>Tevogen believes these and other strategic acquisition initiatives could support the Company’s evolution into http://www.streetinsider.com/Globe+Newswire/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html Thu, 28 May 2026 12:30:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Globe+Newswire/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html <p>WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=EUcdivTuGvletcA08jAdFYmbip2qCrwA5b-gIoecUvUCkaSPXT7zk6IPCHYsP84OVLNTRsUiXTm4_1zlY9Rzzw==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4dIpR_vpvIwuP9gBnkY-EepARo1hOOySfkS2LU7XslZoS2NyrmvJLe9pEWs5pX7X09YJsEASBJghEUn6HC6i087BSZzSN7zDFOiV2p7rCPQoHIU8lpmwU3I4uLAoASpg" rel="nofollow" target="_blank">TVGN</a>) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue. These initiatives include the Company’s previously announced evaluation of a contract research organization (“CRO”), along with additional strategic acquisition opportunities aligned with Tevogen’s broader healthcare platform.</p> <p>Tevogen believes these and other strategic acquisition initiatives could support the Company’s evolution into http://www.streetinsider.com/Globe+Newswire/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html Thu, 28 May 2026 12:30:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Globe+Newswire/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html <p>WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=EUcdivTuGvletcA08jAdFYmbip2qCrwA5b-gIoecUvUCkaSPXT7zk6IPCHYsP84OVLNTRsUiXTm4_1zlY9Rzzw==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=4dIpR_vpvIwuP9gBnkY-EepARo1hOOySfkS2LU7XslZoS2NyrmvJLe9pEWs5pX7X09YJsEASBJghEUn6HC6i087BSZzSN7zDFOiV2p7rCPQoHIU8lpmwU3I4uLAoASpg" rel="nofollow" target="_blank">TVGN</a>) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue. These initiatives include the Company’s previously announced evaluation of a contract research organization (“CRO”), along with additional strategic acquisition opportunities aligned with Tevogen’s broader healthcare platform.</p> <p>Tevogen believes these and other strategic acquisition initiatives could support the Company’s evolution into http://www.streetinsider.com/Globe+Newswire/Tevogen+Advances+Strategic+Acquisition+Initiatives+with+Potential+to+Support+Approximately+%24100+Million+in+Combined+Annual+Revenue/26564357.html Thu, 28 May 2026 12:30:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Corporate+News/Tevogen+reports+51%25+reduction+in+operational+losses+for+2025/26512334.html <p>Tevogen Bio Holdings Inc. (NASDAQ: TVGN) reported a 51% reduction in operational losses for full year 2025, according to a letter to shareholders from CEO Dr. Ryan Saadi dated May 18, 2026.</p> <p>The company's loss from operations declined from $53.6 million in 2024 to $26.1 million in 2025. The improvement continued in the first quarter of 2026, with operational losses decreasing to $5.4 million, representing a 48% improvement compared to the same period in 2025.</p> <p>During this period, Tevogen established its Tevogen.AI initiative and expanded its cell therapy product pipeline while maintaining what the company described as disciplined capital allocation practices.</p> <p>The Warren, http://www.streetinsider.com/Corporate+News/Tevogen+reports+51%25+reduction+in+operational+losses+for+2025/26512334.html Mon, 18 May 2026 12:15:15 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Corporate+News/Tevogen+reports+51%25+reduction+in+operational+losses+for+2025/26512334.html <p>Tevogen Bio Holdings Inc. (NASDAQ: TVGN) reported a 51% reduction in operational losses for full year 2025, according to a letter to shareholders from CEO Dr. Ryan Saadi dated May 18, 2026.</p> <p>The company's loss from operations declined from $53.6 million in 2024 to $26.1 million in 2025. The improvement continued in the first quarter of 2026, with operational losses decreasing to $5.4 million, representing a 48% improvement compared to the same period in 2025.</p> <p>During this period, Tevogen established its Tevogen.AI initiative and expanded its cell therapy product pipeline while maintaining what the company described as disciplined capital allocation practices.</p> <p>The Warren, http://www.streetinsider.com/Corporate+News/Tevogen+reports+51%25+reduction+in+operational+losses+for+2025/26512334.html Mon, 18 May 2026 12:15:15 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Corporate+News/Tevogen+reports+51%25+reduction+in+operational+losses+for+2025/26512334.html <p>Tevogen Bio Holdings Inc. (NASDAQ: TVGN) reported a 51% reduction in operational losses for full year 2025, according to a letter to shareholders from CEO Dr. Ryan Saadi dated May 18, 2026.</p> <p>The company's loss from operations declined from $53.6 million in 2024 to $26.1 million in 2025. The improvement continued in the first quarter of 2026, with operational losses decreasing to $5.4 million, representing a 48% improvement compared to the same period in 2025.</p> <p>During this period, Tevogen established its Tevogen.AI initiative and expanded its cell therapy product pipeline while maintaining what the company described as disciplined capital allocation practices.</p> <p>The Warren, http://www.streetinsider.com/Corporate+News/Tevogen+reports+51%25+reduction+in+operational+losses+for+2025/26512334.html Mon, 18 May 2026 12:15:15 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Corporate+News/Tevogen+reports+51%25+reduction+in+operational+losses+for+2025/26512334.html <p>Tevogen Bio Holdings Inc. (NASDAQ: TVGN) reported a 51% reduction in operational losses for full year 2025, according to a letter to shareholders from CEO Dr. Ryan Saadi dated May 18, 2026.</p> <p>The company's loss from operations declined from $53.6 million in 2024 to $26.1 million in 2025. The improvement continued in the first quarter of 2026, with operational losses decreasing to $5.4 million, representing a 48% improvement compared to the same period in 2025.</p> <p>During this period, Tevogen established its Tevogen.AI initiative and expanded its cell therapy product pipeline while maintaining what the company described as disciplined capital allocation practices.</p> <p>The Warren, http://www.streetinsider.com/Corporate+News/Tevogen+reports+51%25+reduction+in+operational+losses+for+2025/26512334.html Mon, 18 May 2026 12:15:15 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Corporate+News/Tevogen+reports+51%25+reduction+in+operational+losses+for+2025/26512334.html <p>Tevogen Bio Holdings Inc. (NASDAQ: TVGN) reported a 51% reduction in operational losses for full year 2025, according to a letter to shareholders from CEO Dr. Ryan Saadi dated May 18, 2026.</p> <p>The company's loss from operations declined from $53.6 million in 2024 to $26.1 million in 2025. The improvement continued in the first quarter of 2026, with operational losses decreasing to $5.4 million, representing a 48% improvement compared to the same period in 2025.</p> <p>During this period, Tevogen established its Tevogen.AI initiative and expanded its cell therapy product pipeline while maintaining what the company described as disciplined capital allocation practices.</p> <p>The Warren, http://www.streetinsider.com/Corporate+News/Tevogen+reports+51%25+reduction+in+operational+losses+for+2025/26512334.html Mon, 18 May 2026 12:15:15 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Press+Releases/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html <p>WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Hgd92M6wxD_7L-Mht9ltbiLY_jD1HbugD4SOgfJL_8DjApElnPgCyS76d5s_7Ycthe3kG9CW6V1ZXgglsyVIww==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BvgruIovWYZKpPXpw976pi8pe1sr6hiay-zsFqPPaxIGGvqeRdn3DTt-mOWWxN9DiR2ZamQKpZZpaEcMR9oo8xQJ5k_xYFDliiHg6BthLVIrzDDB_HGOTDx34VUSpw4k" rel="nofollow" target="_blank">TVGN</a>).</p> <p>Dear Shareholders,</p> <p>Since Tevogen’s 2024 public listing, we have remained focused on building a sustainable, revenue-oriented healthcare enterprise while maintaining discipline in how we allocate capital.</p> <p>We have delivered consistent operational improvement while continuing to advance our strategic growth priorities. Loss from operations declined 51% from $53.6 million in full year 2024 to $26.1 million in full year 2025. This progress continued in the first quarter of 2026, with loss http://www.streetinsider.com/Press+Releases/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html Mon, 18 May 2026 12:15:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Press+Releases/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html <p>WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Hgd92M6wxD_7L-Mht9ltbiLY_jD1HbugD4SOgfJL_8DjApElnPgCyS76d5s_7Ycthe3kG9CW6V1ZXgglsyVIww==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BvgruIovWYZKpPXpw976pi8pe1sr6hiay-zsFqPPaxIGGvqeRdn3DTt-mOWWxN9DiR2ZamQKpZZpaEcMR9oo8xQJ5k_xYFDliiHg6BthLVIrzDDB_HGOTDx34VUSpw4k" rel="nofollow" target="_blank">TVGN</a>).</p> <p>Dear Shareholders,</p> <p>Since Tevogen’s 2024 public listing, we have remained focused on building a sustainable, revenue-oriented healthcare enterprise while maintaining discipline in how we allocate capital.</p> <p>We have delivered consistent operational improvement while continuing to advance our strategic growth priorities. Loss from operations declined 51% from $53.6 million in full year 2024 to $26.1 million in full year 2025. This progress continued in the first quarter of 2026, with loss http://www.streetinsider.com/Press+Releases/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html Mon, 18 May 2026 12:15:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Press+Releases/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html <p>WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Hgd92M6wxD_7L-Mht9ltbiLY_jD1HbugD4SOgfJL_8DjApElnPgCyS76d5s_7Ycthe3kG9CW6V1ZXgglsyVIww==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BvgruIovWYZKpPXpw976pi8pe1sr6hiay-zsFqPPaxIGGvqeRdn3DTt-mOWWxN9DiR2ZamQKpZZpaEcMR9oo8xQJ5k_xYFDliiHg6BthLVIrzDDB_HGOTDx34VUSpw4k" rel="nofollow" target="_blank">TVGN</a>).</p> <p>Dear Shareholders,</p> <p>Since Tevogen’s 2024 public listing, we have remained focused on building a sustainable, revenue-oriented healthcare enterprise while maintaining discipline in how we allocate capital.</p> <p>We have delivered consistent operational improvement while continuing to advance our strategic growth priorities. Loss from operations declined 51% from $53.6 million in full year 2024 to $26.1 million in full year 2025. This progress continued in the first quarter of 2026, with loss http://www.streetinsider.com/Press+Releases/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html Mon, 18 May 2026 12:15:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Press+Releases/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html <p>WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Hgd92M6wxD_7L-Mht9ltbiLY_jD1HbugD4SOgfJL_8DjApElnPgCyS76d5s_7Ycthe3kG9CW6V1ZXgglsyVIww==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BvgruIovWYZKpPXpw976pi8pe1sr6hiay-zsFqPPaxIGGvqeRdn3DTt-mOWWxN9DiR2ZamQKpZZpaEcMR9oo8xQJ5k_xYFDliiHg6BthLVIrzDDB_HGOTDx34VUSpw4k" rel="nofollow" target="_blank">TVGN</a>).</p> <p>Dear Shareholders,</p> <p>Since Tevogen’s 2024 public listing, we have remained focused on building a sustainable, revenue-oriented healthcare enterprise while maintaining discipline in how we allocate capital.</p> <p>We have delivered consistent operational improvement while continuing to advance our strategic growth priorities. Loss from operations declined 51% from $53.6 million in full year 2024 to $26.1 million in full year 2025. This progress continued in the first quarter of 2026, with loss http://www.streetinsider.com/Press+Releases/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html Mon, 18 May 2026 12:15:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Press+Releases/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html <p>WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Hgd92M6wxD_7L-Mht9ltbiLY_jD1HbugD4SOgfJL_8DjApElnPgCyS76d5s_7Ycthe3kG9CW6V1ZXgglsyVIww==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BvgruIovWYZKpPXpw976pi8pe1sr6hiay-zsFqPPaxIGGvqeRdn3DTt-mOWWxN9DiR2ZamQKpZZpaEcMR9oo8xQJ5k_xYFDliiHg6BthLVIrzDDB_HGOTDx34VUSpw4k" rel="nofollow" target="_blank">TVGN</a>).</p> <p>Dear Shareholders,</p> <p>Since Tevogen’s 2024 public listing, we have remained focused on building a sustainable, revenue-oriented healthcare enterprise while maintaining discipline in how we allocate capital.</p> <p>We have delivered consistent operational improvement while continuing to advance our strategic growth priorities. Loss from operations declined 51% from $53.6 million in full year 2024 to $26.1 million in full year 2025. This progress continued in the first quarter of 2026, with loss http://www.streetinsider.com/Press+Releases/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html Mon, 18 May 2026 12:15:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Globe+Newswire/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html <p>WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Hgd92M6wxD_7L-Mht9ltbiLY_jD1HbugD4SOgfJL_8DjApElnPgCyS76d5s_7Ycthe3kG9CW6V1ZXgglsyVIww==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BvgruIovWYZKpPXpw976pi8pe1sr6hiay-zsFqPPaxIGGvqeRdn3DTt-mOWWxN9DiR2ZamQKpZZpaEcMR9oo8xQJ5k_xYFDliiHg6BthLVIrzDDB_HGOTDx34VUSpw4k" rel="nofollow" target="_blank">TVGN</a>).</p> <p>Dear Shareholders,</p> <p>Since Tevogen’s 2024 public listing, we have remained focused on building a sustainable, revenue-oriented healthcare enterprise while maintaining discipline in how we allocate capital.</p> <p>We have delivered consistent operational improvement while continuing to advance our strategic growth priorities. Loss from operations declined 51% from $53.6 million in full year 2024 to $26.1 million in full year 2025. This progress continued in the first quarter of 2026, with loss http://www.streetinsider.com/Globe+Newswire/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html Mon, 18 May 2026 12:15:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Globe+Newswire/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html <p>WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Hgd92M6wxD_7L-Mht9ltbiLY_jD1HbugD4SOgfJL_8DjApElnPgCyS76d5s_7Ycthe3kG9CW6V1ZXgglsyVIww==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BvgruIovWYZKpPXpw976pi8pe1sr6hiay-zsFqPPaxIGGvqeRdn3DTt-mOWWxN9DiR2ZamQKpZZpaEcMR9oo8xQJ5k_xYFDliiHg6BthLVIrzDDB_HGOTDx34VUSpw4k" rel="nofollow" target="_blank">TVGN</a>).</p> <p>Dear Shareholders,</p> <p>Since Tevogen’s 2024 public listing, we have remained focused on building a sustainable, revenue-oriented healthcare enterprise while maintaining discipline in how we allocate capital.</p> <p>We have delivered consistent operational improvement while continuing to advance our strategic growth priorities. Loss from operations declined 51% from $53.6 million in full year 2024 to $26.1 million in full year 2025. This progress continued in the first quarter of 2026, with loss http://www.streetinsider.com/Globe+Newswire/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html Mon, 18 May 2026 12:15:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW http://www.streetinsider.com/Globe+Newswire/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html <p>WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Hgd92M6wxD_7L-Mht9ltbiLY_jD1HbugD4SOgfJL_8DjApElnPgCyS76d5s_7Ycthe3kG9CW6V1ZXgglsyVIww==" rel="nofollow" target="_blank">Tevogen</a> (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=BvgruIovWYZKpPXpw976pi8pe1sr6hiay-zsFqPPaxIGGvqeRdn3DTt-mOWWxN9DiR2ZamQKpZZpaEcMR9oo8xQJ5k_xYFDliiHg6BthLVIrzDDB_HGOTDx34VUSpw4k" rel="nofollow" target="_blank">TVGN</a>).</p> <p>Dear Shareholders,</p> <p>Since Tevogen’s 2024 public listing, we have remained focused on building a sustainable, revenue-oriented healthcare enterprise while maintaining discipline in how we allocate capital.</p> <p>We have delivered consistent operational improvement while continuing to advance our strategic growth priorities. Loss from operations declined 51% from $53.6 million in full year 2024 to $26.1 million in full year 2025. This progress continued in the first quarter of 2026, with loss http://www.streetinsider.com/Globe+Newswire/Letter+to+Shareholders+from+CEO+Dr.+Ryan+Saadi/26512331.html Mon, 18 May 2026 12:15:00 -0400 A.06270839 O.34653200 O.54782335 TVGN TVGNW